{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:50:44Z","timestamp":1791229844172,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T00:00:00Z","timestamp":1451692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Ministry of Science and Technology"},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"crossref","award":["CMRPG3C0932\/3"],"award-info":[{"award-number":["CMRPG3C0932\/3"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"crossref","award":["CRRPG3D0021\/2"],"award-info":[{"award-number":["CRRPG3D0021\/2"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"crossref","award":["CRRPG3D0031"],"award-info":[{"award-number":["CRRPG3D0031"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"crossref","award":["CMRPG3C0941-3"],"award-info":[{"award-number":["CMRPG3C0941-3"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.tjog.2015.12.004","type":"journal-article","created":{"date-parts":[[2016,2,27]],"date-time":"2016-02-27T10:30:41Z","timestamp":1456569041000},"page":"3-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors"],"prefix":"10.1016","volume":"55","author":[{"given":"Angel","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2015.12.004_bib1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/nature07958","article-title":"Origin and function of ubiquitin-like proteins","volume":"458","author":"Hochstrasser","year":"2009","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.tjog.2015.12.004_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0305-7372(03)00080-X","article-title":"Clinical update: proteasome inhibitors in hematologic malignancies","volume":"29","author":"Richardson","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.tjog.2015.12.004_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids","volume":"8","author":"Adams","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.tjog.2015.12.004_bib4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/2040620713511176","article-title":"From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and\/or refractory multiple myeloma","volume":"4","author":"Siegel","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.tjog.2015.12.004_bib5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ctrv.2014.02.005","article-title":"Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview","volume":"40","author":"Jakubowiak","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.tjog.2015.12.004_bib6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.seminhematol.2012.04.002","article-title":"Targeting the ubiquitin\u00a0+ proteasome system in solid tumors","volume":"49","author":"Driscoll","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.tjog.2015.12.004_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.seminhematol.2012.04.010","article-title":"Bortezomib combination therapy in multiple myeloma","volume":"49","author":"Kapoor","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.tjog.2015.12.004_bib8","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tjog.2015.12.004_bib9","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/ERC-14-0005","article-title":"The ubiquitin\u2013proteasome system: opportunities for therapeutic intervention in solid tumors","volume":"22","author":"Johnson","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.tjog.2015.12.004_bib10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/CAD.0000000000000222","article-title":"Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer","volume":"26","author":"Ding","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.tjog.2015.12.004_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3816\/CLC.2011.n.004","article-title":"Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial","volume":"12","author":"Lara","year":"2011","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.tjog.2015.12.004_bib12","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/annonc\/mdp390","article-title":"Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"21","author":"Chung","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tjog.2015.12.004_bib13","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1200\/JCO.2007.14.0152","article-title":"Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study","volume":"26","author":"Kozuch","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2015.12.004_bib14","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hed.23046","volume":"35","author":"Gilbert","year":"2013","journal-title":"Head Neck"},{"key":"10.1016\/j.tjog.2015.12.004_bib15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","article-title":"A\u00a0phase I\/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors","volume":"72","author":"Papadopoulos","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.tjog.2015.12.004_bib16","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s10637-011-9766-6","article-title":"Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in\u00a0vitro assessments of the combination","volume":"30","author":"Millward","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.tjog.2015.12.004_bib17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejca.2012.09.009","article-title":"A\u00a0first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma","volume":"49","author":"Gallerani","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tjog.2015.12.004_bib18","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1200\/JCO.2005.16.006","article-title":"Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer","volume":"23","author":"Aghajanian","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2015.12.004_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2007.08.071","article-title":"Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer","volume":"108","author":"Ramirez","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2015.12.004_bib20","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ijrobp.2011.09.023","article-title":"Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies","volume":"83","author":"Kubicek","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.tjog.2015.12.004_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/JTO.0b013e3181915052","article-title":"Bortezomib plus gemcitabine\/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)","volume":"4","author":"Davies","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.tjog.2015.12.004_bib22","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/JTO.0b013e31824de2fa","article-title":"Phase-I\/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Piperdi","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.tjog.2015.12.004_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/JTO.0000000000000383","article-title":"A\u00a0Phase I\/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321","volume":"10","author":"Zhao","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.tjog.2015.12.004_bib24","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/j.ejca.2013.05.008","volume":"49","author":"O'Brien","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tjog.2015.12.004_bib25","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/JTO.0b013e31816de276","article-title":"Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B)","volume":"3","author":"Jatoi","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.tjog.2015.12.004_bib26","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1002\/cncr.25191","article-title":"A\u00a0study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study","volume":"116","author":"Croghan","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.tjog.2015.12.004_bib27","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/IGC.0b013e318251051a","article-title":"An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens","volume":"22","author":"Parma","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2015.12.004_bib28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrd1159","article-title":"Bortezomib","volume":"2","author":"Paramore","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.tjog.2015.12.004_bib29","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1038\/cddis.2013.38","article-title":"Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells","volume":"4","author":"Kao","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.tjog.2015.12.004_bib30","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","article-title":"STATs in oncogenesis","volume":"19","author":"Bowman","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.tjog.2015.12.004_bib31","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1073\/pnas.95.13.7556","article-title":"Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice","volume":"95","author":"Kaplan","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tjog.2015.12.004_bib32","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1172\/JCI119869","article-title":"B\u00a0lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues","volume":"100","author":"Frank","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.tjog.2015.12.004_bib33","doi-asserted-by":"crossref","first-page":"9212","DOI":"10.1073\/pnas.96.16.9212","article-title":"Distinctive gene expression patterns in human mammary epithelial cells and breast cancers","volume":"96","author":"Perou","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tjog.2015.12.004_bib34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-015-0135-3","article-title":"Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis","volume":"8","author":"Bustany","year":"2015","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.tjog.2015.12.004_bib35","first-page":"2757","article-title":"Modulation of cisplatin cytotoxicity due to its combination with bortezomib and the nature of its administration","volume":"31","author":"Al-Eisawi","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.tjog.2015.12.004_bib36","first-page":"707","article-title":"Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors","volume":"36","author":"Pasquini","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.tjog.2015.12.004_bib37","doi-asserted-by":"crossref","first-page":"31440","DOI":"10.1016\/S0021-9258(19)84056-5","article-title":"Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa","volume":"281","author":"Fribley","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.tjog.2015.12.004_bib38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc3262","article-title":"Deconvoluting the context-dependent role for autophagy in cancer","volume":"12","author":"White","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.tjog.2015.12.004_bib39","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4161\/auto.6.3.11625","article-title":"Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer","volume":"6","author":"Dalby","year":"2010","journal-title":"Autophagy"},{"issue":"Suppl.\u00a08","key":"10.1016\/j.tjog.2015.12.004_bib40","article-title":"Molecular approaches to personalizing management of ovarian cancer","volume":"22","author":"Bast","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tjog.2015.12.004_bib41","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/ncb0910-823","article-title":"Autophagy in mammalian development and differentiation","volume":"12","author":"Mizushima","year":"2010","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.tjog.2015.12.004_bib42","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4161\/auto.4600","article-title":"How to interpret LC3 immunoblotting","volume":"3","author":"Mizushima","year":"2007","journal-title":"Autophagy"},{"key":"10.1016\/j.tjog.2015.12.004_bib43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/onc.2009.343","article-title":"Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells","volume":"29","author":"Zhu","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.tjog.2015.12.004_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4161\/auto.6.1.10323","article-title":"Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells","volume":"6","author":"Periyasamy-Thandavan","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.tjog.2015.12.004_bib45","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/ncomms3799","article-title":"Autophagy proteins regulate ERK phosphorylation","volume":"4","author":"Martinez-Lopez","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjog.2015.12.004_bib46","doi-asserted-by":"crossref","first-page":"16667","DOI":"10.1074\/jbc.M210998200","article-title":"Amino acids interfere with the ERK1\/2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells","volume":"278","author":"Pattingre","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.tjog.2015.12.004_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4161\/auto.3424","article-title":"Control of the autophagy maturation step by the MAPK ERK and p38: lessons from environmental carcinogens","volume":"3","author":"Corcelle","year":"2007","journal-title":"Autophagy"},{"key":"10.1016\/j.tjog.2015.12.004_bib48","doi-asserted-by":"crossref","first-page":"e1510","DOI":"10.1038\/cddis.2014.468","article-title":"Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation","volume":"5","author":"Kao","year":"2014","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.tjog.2015.12.004_bib49","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/onc.2011.290","article-title":"NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response","volume":"31","author":"Zhang","year":"2012","journal-title":"Oncogene"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455915002879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455915002879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T18:13:54Z","timestamp":1760897634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455915002879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1028455915002879"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2015.12.004","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2015.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}